Search

Search Results

1. Secular trends and regional variations in pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) among children and adolescents in Germany

   Background

   The study aim was to examine the secular trends and regional variations in pharmacotherapy of children and adolescents with...

   Manas K. Akmatov, Jakob Holstiege, Jörg Bätzing in BMC Psychiatry

   Article Open access 14 August 2021
   

2. Atomoxetine/methylphenidate

   in Reactions Weekly

   Article 07 September 2019

3. Consumption of methylphenidate and atomoxetine in the private healthcare sector in South Africa: a longitudinal study

   Background Globally Attention-Deficit/Hyperactivity Disorder (ADHD) has been in the spotlight. Despite some controversies, treatment of ADHD remains...

   Ashmitha Premchand Munasur-Naidoo, Ilse Truter in International Journal of Clinical Pharmacy

   Article 16 July 2019
   

4. Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study

   Introduction

   This study aimed to estimate risks of cardiovascular and cerebrovascular events in patients treated with lisdexamfetamine dimesylate...

   Joan Forns, Elena Dudukina, ... Cristina Rebordosa in Neurology and Therapy

   Article Open access 26 August 2022
   

5. Psychostimulants/Atomoxetine and Serious Cardiovascular Events in Children with ADHD or Autism Spectrum Disorder

   Background

   Psychostimulants and atomoxetine have been shown to increase blood pressure, heart rate, and QT interval in children and adolescents;...

   Richard Houghton, Frank de Vries, Georg Loss in CNS Drugs

   Article Open access 25 November 2019

6. In utero exposure to ADHD medication and long-term offspring outcomes

   Attention Deficit Hyperactivity Disorder (ADHD) medication is increasingly being used during pregnancy. Concerns have been raised as to whether ADHD...

   Kathrine Bang Madsen, Thalia K. Robakis, ... Veerle Bergink in Molecular Psychiatry

   Article 09 February 2023
   

7. Atomoxetine/fluoxetine interactions

   in Reactions Weekly

   Article 27 July 2019

8. The orphan receptor GPR88 controls impulsivity and is a risk factor for Attention-Deficit/Hyperactivity Disorder

   The neural orphan G protein coupled receptor GPR88 is predominant in the striatum and cortex of both rodents and humans, and considered a potential...

   Sami Ben Hamida, Sarojini M. Sengupta, ... Brigitte L. Kieffer in Molecular Psychiatry

   Article 08 September 2022
   

9. Atomoxetine

   in Reactions Weekly

   Article 18 May 2019

10. New pharmacological and neuromodulation approaches for impulsive-compulsive behaviors in Parkinson’s disease

    Introduction

    A significant proportion of patients with Parkinson’s disease (PD) display a set of impulsive-compulsive behaviors at some point during...

    Giacomo Grassi, Giovanni Albani, ... Silvia Ramat in Neurological Sciences

    Article 14 April 2021
    

11. Atomoxetine

    in Reactions Weekly

    Article 23 March 2019

12. Trigeminal nerve stimulation: a recently approved treatment approach in attention deficit hyperactivity disorder

    Attention-deficit hyperactivity disorder (ADHD) with its high prevalence is a growing area of concern and research, whereas exact underlying...

    Mazlum Çöpür, Sidar Çöpür in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

    Article Open access 26 July 2021

13. New insights into precocious puberty and ADHD: a nationwide cohort study

    Background

    Attention deficit-hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in children; however, studies...

    Li-Fan Pai, Der-Shiun Wang, ... Der-Ming Chu in Pediatric Research

    Article 26 March 2022
    

14. Multiple drugs

    in Reactions Weekly

    Article 07 October 2023

15. Atomoxetine/unspecified central nervous system stimulant

    in Reactions Weekly

    Article 15 June 2019

16. Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis

    Background

    There is still no approved medication for the core symptoms of autism spectrum disorder (ASD). This network meta-analysis investigated...

    Spyridon Siafis, Oğulcan Çıray, ... Stefan Leucht in Molecular Autism

    Article Open access 04 March 2022
    

17. Non-serious case reports

    in Reactions Weekly

    Article 14 October 2023

18. Multiple drugs

    in Reactions Weekly

    Article 11 November 2023

19. Multiple drugs

    in Reactions Weekly

    Article 09 September 2023

20. Multiple drugs

    in Reactions Weekly

    Article 18 November 2023